QIPT Stock Forecast & Price Target

Quipt Home Medical Corp is projected to achieve an AEBITDA of $55.2 million, reflecting a slight improvement in margin to 23.2%, which underscores a conservative yet optimistic revenue outlook. Management has indicated more stable trends in equipment rental and resupply as fiscal Q3 2025 progresses, suggesting a strengthening operational environment. Additionally, the consistent cost of inventory sold as a percentage of revenue, held at 27.9%, indicates effective cost management and overall financial stability, contributing to a positive long-term outlook for the company.

Quipt Home Medical Corp reported a second-quarter revenue of $57.4 million, which fell short of the $61.8 million consensus, reflecting a year-over-year decline of 6% and a quarter-over-quarter decrease of 6.5%. The company faced multiple headwinds including decreased patient referrals from Humana's PPO plans, the termination of a significant supply contract, and lower-than-expected resupply volumes due to patient deductible resets. Additionally, respiratory resupply setups and deliveries declined by 4% year-over-year, further indicating struggles in volume growth that exacerbated the overall financial performance.